Join the Risperdal group to help and get support from people like you.
Risperdal News
Weekly LYN-005 Provides Sustained Risperidone Release in Schizophrenia
WEDNESDAY, June 18, 2025 – For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published online June 11 in...
Innovative Once-Weekly Risperidone Capsule Helps Quell Schizophrenia Symptoms
MONDAY, June 16, 2025 — A new breakthrough can help people with schizophrenia keep up with their psychiatric meds, researchers said. A pill taken just once a week, gradually releasing medicine from w...
FDA Approves Perseris (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
SLOUGH, England and RICHMOND, Va., July 27, 2018 /PRNewswire/ – Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved Perseris, the first...
FDA Medwatch Alert: Risperdal (risperidone) and Risperidone: Recall - Uncharacteristic Odor
ISSUE: Ortho-McNeil-Janssen Pharmaceuticals notified healthcare professionals and the public of a recall of specific lots of Risperdal (risperidone) 3mg tablets and risperidone 2mg tablets. The ...
FDA Medwatch Alert: Risperidone (Risperdal) and Ropinirole (Requip): Medication Errors - Name Confusion
ISSUE: FDA notified healthcare professionals and the public of medication error reports in which patients were given risperidone (Risperdal) instead of ropinirole (Requip) and vice versa. In some...
FDA Medwatch Alert: Risperdal (risperidone) - Aug 4, 2004
FDA and Janssen revised the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Risperdal. MedWatch is posting a revised version of a letter...
FDA Medwatch Alert: Risperdal (risperidone) - Apr 25, 2003
Janssen Pharmaceutica and FDA revised the WARNINGS section of the prescribing information for Risperdal (risperidone), indicated for the treatment of schizophrenia. Cerebrovascular adverse events...
FDA Medwatch Alert: Antipsychotics, Conventional and Atypical
[Posted 06/16/2008] FDA notified healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for...
FDA Medwatch Alert: Atypical Antipsychotic Drugs
The Food and Drug Administration has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved, “off-label” us...
Further information
Related condition support groups
Autism, Schizoaffective Disorder, Bipolar Disorder, Schizophrenia, Mania